Verndari, Inc.
Verndari, Inc. is an early-stage biotechnology company dedicated to transforming vaccine delivery through next-generation science and technology. Their mission is to develop and commercialize a novel intradermal vaccine delivery device called VaxiPatch™, which aims to improve global health by providing more effective, lower-cost vaccine delivery that is dose-sparing, potentially more efficacious, and pain-free. The company focuses on creating a single-dose vaccination kit using intradermal microarray technology, eliminating the need for cold chain shipping, and facilitating high-volume automated manufacturing. Verndari is committed to building a brighter future through more effective delivery of life-saving vaccines.
Industries
Nr. of Employees
small (1-50)
Verndari, Inc.
Sacramento, California, United States, North America
Products
Intradermal microneedle patch vaccine delivery system
A single-dose, patch-format intradermal vaccine delivery system using microneedle microarrays intended to enable dose sparing, pain-reduced administration, thermostable presentations, and compatibility with automated manufacturing.
Intradermal microneedle patch vaccine delivery system
A single-dose, patch-format intradermal vaccine delivery system using microneedle microarrays intended to enable dose sparing, pain-reduced administration, thermostable presentations, and compatibility with automated manufacturing.
Services
Preclinical evaluation of patch-delivered vaccine candidates
Design and execution of preclinical studies in partnership with academic research centers to assess immunogenicity and safety of vaccines delivered via microneedle patches.
Formulation and adjuvant development for patch vaccines
Adjuvant formulation (liposome/nanodisc) development, extrusion-based liposome preparation, and loading methods to optimize stability and immune response in patch-format vaccines.
Analytical method development and potency testing
Development and validation of high-sensitivity analytical assays (e.g., HPLC-ELSD) and serological potency assays to quantify adjuvant components and vaccine potency for patch-format products.
Manufacturing specification and scale-up consulting for automated patch production
Provision of engineering specifications and requirements to enable automated, high-volume manufacturing of microneedle patch vaccines.
Regulatory planning and pre-IND support
Regulatory planning activities including preparation for and conduct of pre-IND meetings with regulatory authorities to support clinical transition of patch-format vaccines.
Preclinical evaluation of patch-delivered vaccine candidates
Design and execution of preclinical studies in partnership with academic research centers to assess immunogenicity and safety of vaccines delivered via microneedle patches.
Formulation and adjuvant development for patch vaccines
Adjuvant formulation (liposome/nanodisc) development, extrusion-based liposome preparation, and loading methods to optimize stability and immune response in patch-format vaccines.
Analytical method development and potency testing
Development and validation of high-sensitivity analytical assays (e.g., HPLC-ELSD) and serological potency assays to quantify adjuvant components and vaccine potency for patch-format products.
Manufacturing specification and scale-up consulting for automated patch production
Provision of engineering specifications and requirements to enable automated, high-volume manufacturing of microneedle patch vaccines.
Regulatory planning and pre-IND support
Regulatory planning activities including preparation for and conduct of pre-IND meetings with regulatory authorities to support clinical transition of patch-format vaccines.
Expertise Areas
- Intradermal vaccine delivery platform development
- Vaccine formulation and thermostabilization
- Adjuvant design and liposomal/nanodisc formulations
- Preclinical vaccine testing and animal-model evaluation
Key Technologies
- Microneedle microarray patches
- Intradermal microarray delivery
- High-density mammalian cell suspension culture (CHO)
- Recombinant protein antigen production (RBD)